azacitidine has been researched along with Bacterial Infections in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gattermann, N; Germing, U; Goette, MC; Haas, R; Kobbe, G; Kuendgen, A; Neukirchen, J; Schroeder, T; Schuck, A | 1 |
| Akria, L; Arad, A; Aviv, A; Braester, A; Dally, N; Filanovsky, K; Gafter-Gvili, A; Gatt, ME; Hellmann, I; Herishanu, Y; Herzog-Tzarfati, K; Leiba, R; Merkel, D; Mittelman, M; Nagler, A; Nemets, A; Ofran, Y; Ronson, A; Rouvio, O; Silbershatz, I; Tadmor, T; Vidal, L; Yeganeh, S | 1 |
| Costa, S; Javier, KP; Linares, M; Orero, M; Ortiz, S; Pérez, PL; Roig, M; Villegas, C | 1 |
| Bainschab, A; Greinix, HT; Krause, R; Quehenberger, F; Sill, H; Wölfler, A; Zebisch, A | 1 |
| Dickinson, M; Seymour, JF; Slavin, MA; Spelman, T; Thursky, KA; Trubiano, JA; Worth, LJ | 1 |
| Aparicio, SA; Carlton, M; Colledge, B; de Algara, TR; Dixon, J; Heuser, M; Humphries, RK; Leung, M; McKinney, S; Tafech, A; Thresher, R; Yap, DB | 1 |
| Aono, K; Hashimoto, K; Hayashi, H; Kondoh, S; Shiraishi, N; Takeda, Y; Yamamoto, H | 1 |
7 other study(ies) available for azacitidine and Bacterial Infections
| Article | Year |
|---|---|
A retrospective study evaluating the impact of infectious complications during azacitidine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Female; Humans; Kaplan-Meier Estimate; Length of Stay; Male; Middle Aged; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Retrospective Studies; Risk Factors | 2017 |
Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Mycoses; Myelodysplastic Syndromes; Platelet Count; Risk Factors; Virus Diseases | 2015 |
Infection Rate and Risk Factors in Patients Treated With Azacitidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Virus Diseases | 2015 |
Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Risk Factors; Virus Diseases | 2016 |
Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Humans; Incidence; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Time Factors | 2017 |
Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Blepharitis; Cell Differentiation; Decitabine; DNA Methylation; Genotype; Hematopoiesis; Hematopoietic Stem Cells; Histone-Lysine N-Methyltransferase; Homozygote; Mice; Mice, Knockout; Myeloid-Lymphoid Leukemia Protein; Neutrophils | 2009 |
Increased metallothionein content in rat liver and kidney following X-irradiation.
Topics: Animals; Azacitidine; Bacterial Infections; Corticosterone; Dose-Response Relationship, Radiation; Kidney; Liver; Male; Metallothionein; Organ Size; Rats; Rats, Inbred Strains; Whole-Body Irradiation; Zinc | 1986 |